
Feb 2 (Reuters) - Sagimet Biosciences Inc SGMT.O:
SAGIMET ANNOUNCES POSITIVE 52-WEEK DATA FROM LICENSE PARTNER ASCLETIS’ OPEN-LABEL PHASE 3 CLINICAL TRIAL EVALUATING THE LONG-TERM SAFETY OF ASC40 (DENIFANSTAT) TABLETS IN PATIENTS WITH MODERATE TO SEVERE ACNE
SAGIMET BIOSCIENCES INC - DENIFANSTAT WELL TOLERATED WITH TEAES INCIDENCE RATE OF 5% OR MORE
SAGIMET BIOSCIENCES INC - DENIFANSTAT SHOWS IMPROVEMENTS IN EFFICACY ENDPOINTS BEYOND 12 WEEKS